US 10,234,463 B2 · Aiding assessment of prognosis in inflammatory disease by measuring octameric PTX3

Abstract

Some embodiments are directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein determining the level of octameric PTX3 includes measuring the total amount of PTX3 present, and measuring the amount of octameric PTX3 present, and calculating the proportion of total PTX3 which is present as octamer, wherein if the proportion of octameric PTX3 is greater than 50%, the subject is identified as a likely non-survivor. Some embodiments are also directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein an elevated level of octameric PTX3 compared to a reference level indicates a reduced likelihood of survival.

Claims13

Dependent claims

A method of collecting information useful in predicting survival or non-survival of a subject who is suspected of having an inflammatory disease, the method comprising:

providing a sample from the subject, the sample including blood, serum, or plasma;
determining the level of octameric PTX3 in the sample, the determining the level of octameric PTX3 including measuring the total amount of PTX3 present, and measuring the amount of octameric PTX3 and monomeric PTX3 present, wherein the amounts of monomeric PTX3 and octameric PTX3 are determined by:
(a) separating the proteins in the sample at least under non-reducing conditions;
and
(b) measuring the amounts of monomeric PTX3 and octameric PTX3 by quantifying the amounts of those forms of PTX3 as separated in step (a);
and
calculating a ratio of octameric PTX3 to monomeric PTX3, wherein the ratio of the octameric PTX3 to the monomeric PTX3 is determined to provide greater discriminatory power compared to NT-proBNP as indicated by ROC curves, and if the ratio of the octameric PTX3 to monomeric PTX3 is greater than 50%, then the subject is identified as a likely non-survivor from the inflammatory disease.

4 more elements

Dependencies are inferred from the claim text.

Aiding assessment of prognosis in inflammatory disease by measuring octameric PTX3

Life of this patent

Aiding assessment of prognosis in inflammatory disease by measuring octameric PTX3

Life of this patent

Abstract

Claims13